Eli Lilly Buys Centessa for $7B, Boosting Brain Health Pipeline

Eli Lilly Acquires Centessa for $7B, Boosting Brain Health Pipeline

Eli Lilly is making a significant move by purchasing biotech firm Centessa for over $7 billion. Centessa specializes in treatments for daytime sleepiness and neurological issues, which could greatly enhance Lillys pipeline in brain health. The company is currently in clinical trials for a new class of drugs targeting narcolepsy and impaired wakefulness. Although Centessa hasnt launched any products yet, their work aligns perfectly with Lillys focus on Alzheimers research. The acquisition could potentially revolutionize the treatment of sleepiness as a side effect of larger diseases like Alzheimers. Investors are optimistic about the deal, betting on broader applications in the future. The upfront payment is $6.3 billion, with an additional $1.5 billion if U.S. regulators approve the drugs. The deal is subject to Centessa shareholder approval, expected later this year. This merger positions Lilly strongly in the fight against sleep disorders and beyond, maintaining momentum in neuro medications.

Support the show:
Get a discount at https://solipillow.com/discount/dnn.

Advertise on DNN:
[email protected]

This is an automated, high-level news summary based on public reporting.
Report issues to [email protected].

View sources & latest updates:
https://sources.thednn.ai/c11f154dc33204f8